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Abstract
The Plasmodium falciparum parasite is an obligate intracellular pathogen whose invasion and
remodeling of the human erythrocyte results in the clinical manifestations of malarial disease. The
functional analysis of erythrocyte determinants of invasion and growth is a relatively unexplored
frontier in malaria research, encompassing studies of natural variation of the erythrocyte, as well
as genomic, biochemical and chemical biological and transgenic approaches. These studies have
allowed the functional analysis of the erythrocyte in vitro, resulting in the discovery of critical
erythrocyte determinants of Plasmodium infection. Here, we will focus on the varied approaches
used for the study of the erythrocyte in Plasmodium infection, with a particular emphasis on
erythrocyte invasion.
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1. Plasmodium and the erythrocyte
Over one-third of the world’s population is at risk of malaria infection, and malaria accounts
for between 655,000 and 1.2 million deaths each year, according to recent reports (WHO,
2010; Murray et al., 2012). Malaria is caused by infection with the protozoan parasite of the
genus Plasmodium. Erythrocyte invasion and growth by Plasmodium spp. parasites is an
obligatory step in the life-cycle of the parasite and central to the virulence of malarial
disease. There are many host and parasite protein interactions that contribute to the process
of invasion and growth (Fig. 1).
Most recent studies have focused on identifying the parasite determinants for invasion into
and growth within erythrocytes. Associative studies have uncovered intriguing associations
between host polymorphisms in erythrocyte proteins, susceptibility to invasion by the
Plasmodium parasite and virulence. Such studies have prompted the need for the direct
functional analysis of erythrocyte determinants, focused on natural variation of the
erythrocyte, genomic approaches, biochemical approaches, chemical biological approaches
or recent transgenic approaches to either deplete, block, inhibit or transgenically alter the
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erythrocyte surface (Fig. 2). Here we review the different approaches that are being
developed for the in vitro functional analysis of the erythrocyte (Table 1), with a special
emphasis on invasion that has been the focus of considerable study.
2. Studies of natural variation of the erythrocyte
Malaria has exerted a detectably strong selective pressure on the human genome. Over the
last few decades, a number of erythrocyte polymorphisms have been found to provide
resistance to malaria. These polymorphisms are often spatially distributed in areas of intense
malaria transmission (Williams, 2006). Polymorphic erythrocyte proteins such as
hemoglobin for sickle cell trait (HbAS) and glucose-6-phosphate dehydrogenase (G6PD)
have been associated with protection from malaria in vivo (Allison et al., 1961; Allison and
Clyde, 1961; Gilles et al., 1967; Ruwende and Hill, 1998), and it has been postulated based
on studies in mice (Min-Oo et al., 2003; Ayi et al., 2004, 2008) that pyruvate kinase
deficiencies could also provide protection in humans (Daily and Sabeti, 2008); however, the
mechanisms governing such protection are poorly understood. These polymorphic
erythrocytes have been used in in vitro assays to determine their relevance to the processes
of Plasmodium invasion, growth and development, protein trafficking and erythrocyte
surface display, and rosetting or cytoadherence (Roth et al., 1983; Fairhurst et al., 2005; Ayi
et al., 2008; Cholera et al., 2008; Cyrklaff et al., 2011). Importantly, these polymorphic
erythrocytes provide specific candidate host proteins that are likely critical in these virulence
processes.
2.1. Invasion
All of the known receptors for erythrocyte invasion belong to polymorphic human blood
group antigen families. A strong body of evidence implicating specific surface receptors in
Plasmodium parasite invasion and growth stems from work examining the role of naturally-
occurring erythrocyte mutants. These erythrocytes completely lack a protein, contain a
partial deletion or are polymorphic - either in sequence or expression level and have
provided valuable clues implicating specific proteins as receptors for invasion. Naturally
occurring mutants have been used both to determine the specificity of binding of different
parasite ligands or to determine the impact of specific mutations on parasite invasion
efficiency. These include glycophorin A null cells (Miller et al., 1977; Pasvol et al., 1982a;
Facer, 1983; Pasvol and Jungery, 1983), glycophorin B null cells (S-s-u) (Pasvol et al.,
1982a; Facer, 1983; Pasvol and Jungery, 1983), glycophorin C mutant and null cells Gerbich
and Leach (Serjeantson, 1989; Lobo et al., 2003; Maier et al., 2003) and Duffy antigen
receptor for chemokines (DARC) null cells (Horuk et al., 1993; Chitnis, 2001). Polymorphic
proteins have also been analyzed, including ABO blood group variants (Fraser et al., 1966;
Cserti and Dzik, 2007; Uneke, 2007; Rowe et al., 2009b), Band 3 deletion mutants (SAO)
(Cortes et al., 2004), and Oka blood group variants of the Basigin protein (BSG) (Crosnier et
al., 2011).
While no known null exists for Complement receptor 1 (CR1), cells with high and low
erythrocyte surface expression of CR1 are common, and these expression level differences
impact Plasmodium falciparum invasion (Spadafora et al., 2010; Tham et al., 2010)
2.2. Protein trafficking and display
While the observation that HbAS is associated with protection from severe malaria was
made decades ago (Allison, 1964) and hemoglobin C (HbC) has also been shown to be
protective (Flint et al., 1998; Agarwal et al., 2000; Modiano et al., 2001), researchers have
been searching for the mechanism of this protection. Plasmodium falciparum invasion and
growth appear to be decreased in HbAS cells in vitro (Friedman, 1978; Pasvol et al., 1978),
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but it has been suggested that other factors must be involved for protection to be observed in
vivo.
Parasite adhesive proteins, such as PfEMP1, are exported to the surface of the infected
eythrocyte where they adhere to host receptors resulting in sequestration of P. falciparum-
infected erythrocytes. It has been found that display of PfEMP1 and cytoadherance is altered
on the surface of HbC containing cells (Fairhurst et al., 2005), and HbAS and HbS
(hemoglobin associated with sickle cell anemia) containing cells (Cholera et al., 2008). A
precise mechanism of abnormal display in HbSC (hemoglobin associated with sickle cell –
hemoglobin C disease) and HbCC (homozygous for hemoglobin C) cells has been recently
proposed (Cyrklaff et al., 2011). Using cryoelectron tomography, researchers were able to
observe that the parasite generates a human actin network to link the developing parasite
with Maurer’s clefts, allowing proper trafficking of adhesive parasite proteins to the surface
of the infected erythrocyte (Cyrklaff et al., 2011). The presence of hemoglobin C or S
resulted in disordered actin networks and aberrant trafficking, possibly making these cells
vulnerable to clearance by the spleen.
Rosetting is a process by which parasitized erythrocytes bind to uninfected erythrocytes,
forming clusters (rosettes) that are thought to contribute to malaria pathology by blocking
blood flow through small vessels (Kaul et al., 1991; Rowe et al., 2009a) and by facilitating
the invasion of merozoites, resulting in increased parasitemia and anemia, as has been
observed in human clinical isolates and in Saimiri monkeys (Rowe et al., 2002; Le Scanf et
al., 2008). Before its role in invasion was appreciated, the CR1 protein was identified as an
erythrocyte receptor important in the process of rosetting (Rowe et al., 1997). Later, ABO
blood group polymorphisms, and in particular blood group O, were found to confer
protection against severe malaria through a mechanism of reduced rosetting (Rowe et al.,
2007).
2.3. Functional genomics to identify novel candidates
While the roles of a few candidate polymorphic proteins have been identified through
associative studies and confirmed in vitro, these known factors cannot explain the entirety of
human genetic resistance to malaria, implying that many genetic factors have yet to be
discovered (Mackinnon et al., 2005). Functional genomics can provide a means of
identifying such novel candidates. In recent years, genome-wide association studies
(GWAS) have provided important insights as to the genetic determinants of diseases. It is
only recently that such tools have been adapted to study genetically highly diverse
populations, such as those found in Africa (Jallow et al., 2009; Teo et al., 2010). One such
study examining GWA with severe malaria in 2,500 Gambian children was able to identify a
single known malaria resistance loci (HbS) (Jallow et al., 2009). The authors concluded that
the insufficient tagging efficiency of a 500 K gene chip array (Affymetrix, USA), in addition
to low allele frequencies and other factors which decreased statistical power, were
responsible for the lack of known and novel malaria resistance loci identified by the GWAS.
However, when deep sequencing and multipoint imputation modeling around the HbS loci
were conducted, the significance of the signal was increased and the causal single nucleotide
polymorphism (SNP) was identified. Further known signals of resistance such as G6PD
polymorphism and susceptibility (such as non-O ABO blood group) were confirmed upon
deep sequencing, but significance levels were not sufficient to be detected by the GWAS
methodology. It was postulated that the weak linkage disequilibrium present in African
populations makes identifying causal variants more difficult and will increase the number of
SNPs required to tag common variants in the population. Additionally, many resistance
markers are present at either low frequencies or have reached fixation – decreasing the
power of GWAS to detect those. Further, the population-specific sequence information is
critical in designing and interpreting GWAS. In African populations resistance mutations
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can arise independently in loci under particularly strong selection and this results in different
causal SNPs in different African populations, complicating the ability to conduct multicenter
replication studies. With advances in sequencing technology and increased sequence
coverage of diverse African populations, perhaps these challenges can be overcome and will
increase the power of the GWAS approach for identifying determinants of malarial disease
in Africa.
3. Biochemical approaches
Numerous biochemical approaches have been applied to identify the host erythrocyte
receptors and the Plasmodium parasite ligands that are involved in the process of merozoite
invasion. The primary challenge with biochemical approaches is stability and the temporal
nature of the protein interactions. While some ligand-receptor interactions have been
successfully identified biochemically (Galinski et al., 1992; Sim et al., 1994; Ogun and
Holder, 1996), many have eluded characterization.
3.1. Enzymatic cleavage
In addition to naturally occurring erythrocyte mutants, which are often rare, studies have
been conducted using enzymatic cleavage to specifically remove non-overlapping sets of
receptors from the surface of the erythrocyte (Binks and Conway, 1999; Okoyeh et al., 1999;
Thompson et al., 2001). The advantage of these studies is that comparisons can be made
between cells from the same donor, minimizing the confounding effects due to genetic
variation. The disadvantage is that enzymatic treatment usually removes many potential
determinants simultaneously. Enzyme-treated erythrocytes have been utilized in various
assays, such as erythrocyte binding assays (EBAs), gel overlay and invasion assays, to
identify receptor-ligand interactions. Each assay is based on differences in protein-protein
interactions between the wild type (mock treated) and enzymatically cleaved erythrocytes.
Whether recombinant proteins are incubated with erythrocytes, washed and eluted, as with
EBAs; native protein gels of treated erythrocytes are run and overlaid with recombinant
ligand as in gel overlays; or whether invasion of viable merozoites into enzyme treated cells
are compared as in standard invasion assays, each assay relies on comparing the interactions
due to the absence of a given set of receptors.
Early studies were done with neuraminidase treatment of erythrocytes to determine
dependence of different strains on sialic acid (Mitchell et al., 1986). Enzymatic cleavage of
erythrocyte receptors with different proteases has been employed to define different
receptors used by the parasite for binding and invasion of the erythrocyte, known as invasion
pathways (Dolan et al., 1990; Reed et al., 2000; Duraisingh et al., 2003). Such
methodologies have allowed for comparisons between invasion pathway utilization for both
laboratory and field isolated parasites (Okoyeh et al., 1999; Baum et al., 2003; Lobo et al.,
2004; Nery et al., 2006; Bei et al., 2007; Deans et al., 2007; Jennings et al., 2007; Lantos et
al., 2009; Gomez-Escobar et al., 2010).
3.2. Antibody mediated blocking and inhibition
For erythrocyte determinants of invasion that are surface exposed, interfering with the
protein’s accessibility to the parasite through blocking antibodies, Fab fragments, or soluble
receptor competition assays, have provided useful clues as to the mechanism of action of
these determinants. High concentrations of antibodies required to inhibit parasite invasion
can cause agglutination of the erythrocytes and changes in membrane rigidity. The use of
Fab fragments can be used to circumvent these issues. While Fab fragments can be useful in
invasion neutralizing experiments, they are not applicable to studies of opsonophagocytosis
via binding of IgG to Fc receptors on phagocytic cells. Antibodies against glycophorin A
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have been shown to inhibit parasite invasion (Pasvol et al., 1982a; Pasvol et al., 1982b;
Jungery, 1985), however this inhibition may be due either to receptor blockage or to an
increase in erythrocyte membrane rigidity (Pasvol et al., 1989). In the case of CR1, certain
monoclonal antibodies were able to disrupt the interaction between the CR1 receptor and its
parasite ligand, PfRh4, in biochemical pull-down experiments (Tham et al., 2010).
Monoclonal antibodies were also shown to potently block the PfRh5-BSG interaction
through binding to BSG at incredibly low inhibitory concentrations (Crosnier et al., 2011).
In addition to blocking the host-parasite interactions with antibodies, soluble erythrocyte
receptors have also been shown to inhibit parasite invasion. Recently, soluble CR1 was
shown to inhibit parasites that relied on PfRh4 for invasion (Tham et al., 2010). Inhibiting
the PfRh5-BSG interaction using pentamerized BSG proved a potent inhibitor of all
laboratory parasite isolates and recently in vitro-adapted Senegalese isolates tested to date,
implying that this interaction may be essential for invasion of all strains (Crosnier et al.,
2011). The fact that targeting a receptor can give such potent cross-strain inhibition gives
credence to the concept of host targeted therapies for malaria. While targeting the parasite
ligand could give rise to rapidly evolving allelic forms, targeting a conserved receptor in the
human host might actually circumvent the issue of polymorphism.
3.3. Identification of novel receptors: AVEXIS
One major challenge has been identifying receptor-ligand interactions due to their often
weak and transient nature. To address this problem, an AVEXIS (avidity-based extracellular
interaction screen) was developed to allow for high throughput screening of low-affinity
protein-protein interactions (Bushell et al., 2008). By multimerizing either the bait or the
prey, the method allows for detection of low affinity interactions that are intractable by
standard biochemical techniques. The AVEXIS system was applied to Plasmodium ligand-
receptor interactions involved in invasion and resulted in the identification of BSG as the
receptor for PfRh5 (Crosnier et al., 2011). While this system successfully identified a major
receptor-ligand interaction, one of the challenges is that only single pass transmembrane
proteins (or proteins with large ectodomains predicted to be soluble) were included in the 40
erythrocyte protein preys. Therefore while some interactions may be identified, others
remain to be discovered.
4. Chemical biological approaches
Besides biochemical approaches, chemical genetic approaches have been useful in
validating existing players in the process of parasite invasion and egress and in identifying
novel candidates. An important role for erythrocyte G-Protein signaling in P. falciparum
invasion and growth was identified through hypotonic erythrocyte lysis, followed by loading
erythrocytes with membrane insoluble protein cargo to inhibit the erythrocyte protein
activity (Murphy et al., 2006). Such experiments with re-sealed modified erythrocytes were
able to establish a requirement of host G-Protein Coupled Receptors (GPCRs) for
Plasmodium invasion. Targeting GPCRs has subsequently been suggested as a novel anti-
malarial strategy, either singly or in combination with other anti-malarial drugs (Murphy et
al., 2006).
In addition to identifying signaling pathways involved in parasite invasion and growth,
chemical genetic approaches have been applied to investigate the role of host proteases in
parasite egress. By treating infected erythrocytes with DCG04—a papain family protease
inhibitor—a specific block in schizont egress was identified (Chandramohanadas et al.,
2009). The protease target for DCG04 was found to be human Calpain-1 through
biochemical approaches (pull-downs with tagged DCG04 followed by mass spectrometry),
and confirmed through hypotonic erythrocyte lysis followed by immunodepletion of the
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protease (Chandramohanadas et al., 2009). Further, small interfering RNA (siRNA) knock-
downs in nucleated human U2OS cells and mouse fibroblast cell lines lacking both calpain-1
and calpain-2 were used in invasion and egress assays for the related apicomplexan parasite
Toxoplasma gondii, and both showed the same egress phenotype. However, while the
method of immunodepletion followed by re-sealing erythrocyte ghosts is suited to the study
of certain cytoplasmic proteins, unfortunately it cannot be applied to the study of
transmembrane proteins such as erythrocyte surface receptors.
Chemical genetic screening to identify Plasmodium Mitogen-activated protein (MAP)
kinase inhibitors of parasite growth unexpectedly identified inhibitors of two mammalian
kinases—PAK1 and MEK1, with no clear orthologs in the Plasmodium genome—that
inhibited blood stage growth of P. falciparum, and both blood and liver stages of
Plasmodium berghei (Sicard et al., 2011). Such studies emphasize the importance of
chemical genetic methods to identify novel host targets, especially in the erythrocyte.
5. Transgenic approaches
While studies using naturally occurring erythrocyte polymorphisms have been useful in
determining the genetic basis of resistance to infection with Plasmodium, as with all studies
of naturally occurring mutants, the paired control by definition is blood from another donor
that is deemed to be wild-type for that polymorphism. These “controls” can be (and often
are) polymorphic at other loci that are not under direct observation, can be of different ages,
and potentially have been handled and stored differently, all of which can significantly
confound the results. One way to truly observe the impact of absence on P. falciparum
invasion and growth is to transgenically modify erythrocytes from the same donor, or
modify them biochemically as with enzymatic treatment.
The in vitro generation of erythrocytes from stem cells has been explored both in terms of
genetic targeting of the erythrocyte to understand function, as well as for targeted stem cell
therapies. Previously, complete differentiation into fully mature erythrocytes required
implantation into non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice
(Miyoshi et al., 1999; Neildez-Nguyen et al., 2002; Puthenveetil et al., 2004). In 2005, a
protocol was developed for the generation of synchronous reticulocytes and fully mature,
enucleated erythrocytes from hematopoietic stem cells completely in vitro and with marked
expansion in numbers from the progenitor cells (Giarratana et al., 2005). The advances in
this methodology made it technically possible to create genetically modified human
erythrocytes in vitro. By targeting the hematopoietic stem cell precursors with lentiviral
constructs designed to stably knock-down or transgenically express proteins, the terminally
differentiated erythrocyte will contain mutations in isogenic backgrounds. The ability to
knock-down protein expression with short hairpin RNAs (shRNAs), ectopically express or
over-express proteins using expression vectors, and perform allelic replacement experiments
has dramatically increased the tool kit available to researchers studying host-parasite
interactions in Plasmodium invasion.
To date, there have been few studies that have utilized this erythrocyte culture system to
genetically modify erythroid cells and erythrocytes in vitro. One study controlled expression
of the surface exposed human blood group antigen Jka (Bagnis et al., 2009) while another
studied the role of hemoglobin switching through regulation by BCL11A (Sankaran et al.,
2009). Additionally, we combined in vitro culture of hematopoietic stem cells to terminally
differentiated enucleated erythrocytes, with lentivirus-delivered shRNA-mediated
knockdown of erythrocyte receptors. Specifically, we targeted glycophorin A (Bei et al.,
2010), a receptor that interacts with PfEBA-175, demonstrating strain-specific differences in
invasion efficiency. We used this approach to deplete erythrocytes of BSG (Crosnier et al.,
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2011), the recently identified receptor for PfRh5, demonstrating that it appears to be
essential for efficient invasion of all strains.
In addition to applying reverse genetic methodologies to the surface receptors of the
erythrocyte utilized by Plasmodium for invasion, transgenic erythrocytes could be generated
to determine the role of depletion of cytoplasmic and cytoskeletal erythrocyte proteins on
pathogenesis related processes such as erythrocyte deformability, parasite protein trafficking
and export, intracellular signaling, species-specific tropism and gametocytogenesis. The
ability to genetically modify the erythrocyte through targeted knock-down, ectopic
expression and/or over-expression of transgenes, allelic replacement, and temporal
expression or depletion of target proteins, lends an additional level of sophistication and
specificity to experiments aimed at identifying and characterizing host-parasite interactions.
Transgenic approaches have been applied to correct erythrocyte disorders such as murine
beta-thalassemia (Imren et al., 2002) and sickle cell disease (Pawliuk et al., 2001), the latter
being corrected in human hematopoietic stem cells transplanted into mice. Recently, the
same authors that pioneered the ex vivo culture of erythrocytes have piloted the use of such
cells for transplant into humans (Giarratana et al., 2011), again broadening the horizon for
how these genetically modified cells might be used in gene therapy. Additionally, with
recent advances in induced pluripotent stem (iPS) cells, there has been increased interest in
the use of gene therapy to repair erythrocyte disorders using autologous cells from the
patient (Lengerke and Daley, 2010).
6. The prospect for future technologies
As the weapons in the arsenal become more advanced and diverse, we are able to target the
host-parasite interface with increasing precision and specificity. Advances in the
methodologies of both human genomics and erythrocyte genetics have identified novel
determinants of Plasmodium infection and have given us the tools with which to interrogate
those. GWASs are being adapted to highly diverse African populations by correcting for
underlying population structure, making studies aimed at determining novel human
determinants of Plasmodium infection more feasible (Teo et al., 2010). While current
reverse genetic methodologies for the erythrocyte have been performed using adult
hematopoietic stem cells (Bagnis et al., 2009; Sankaran et al., 2009; Bei et al., 2010;
Crosnier et al., 2011), the potential to apply such methodologies to continuously self-
renewing iPS cells is the next goal. For instance, gene knockouts might be possible using
iPS cells. As reverse genetic methodologies are being adapted and applied to the erythrocyte
to identify and confirm suspected determinants of Plasmodium infection, forward genetic
screens to identify novel determinants are becoming a reality.
As these methodologies develop and are refined, one can envision applications not only in
the field of Plasmodium biology, but also in the fields of erythrocyte biology, hematology
and gene therapy. While these methods enable the identification and validation of
erythrocyte determinants of Plasmodium infection, it is our hope that they will also
contribute to the development of potential host-targeted therapies for malaria and other
diseases.
Acknowledgments
We acknowledge the following support: Centers for Disease Control and Prevention, USA (grant R36
CK000119-01 to AKB); Burroughs Welcome Fund New Investigator in the Pathogenesis of Infectious Diseases,
USA (award to MTD); National Institutes of Health, USA (grant R01AI057919 and R01AI091787 to MTD); Bill &
Melinda Gates Foundation Grand Challenges Explorations Grant (MTD).
Bei and Duraisingh Page 7














Agarwal A, Guindo A, Cissoko Y, Taylor JG, Coulibaly D, Kone A, Kayentao K, Djimde A, Plowe
CV, Doumbo O, Wellems TE, Diallo D. Hemoglobin C associated with protection from severe
malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S.
Blood. 2000; 96:2358–2363. [PubMed: 11001883]
Allison AC, Charles LJ, Mc GI. Erythrocyte glucose-6-phosphate dehydrogenase deficiency in West
Africa. Nature. 1961; 190:1198–1199. [PubMed: 13682584]
Allison AC, Clyde DF. Malaria in African children with deficient erythrocyte glucose-6-phosphate
dehydrogenase. Br Med J. 1961; 1:1346–1349. [PubMed: 13682585]
Allison AC. Polymorphism and Natural Selection in Human Populations. Cold Spring Harb Symp
Quant Biol. 1964; 29:137–149. [PubMed: 14278460]
Ayi K, Turrini F, Piga A, Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a
common mechanism that may explain protection against falciparum malaria in sickle trait and beta-
thalassemia trait. Blood. 2004; 104:3364–3371. [PubMed: 15280204]
Ayi K, Min-Oo G, Serghides L, Crockett M, Kirby-Allen M, Quirt I, Gros P, Kain KC. Pyruvate
kinase deficiency and malaria. N Engl J Med. 2008; 358:1805–1810. [PubMed: 18420493]
Bagnis C, Chapel S, Chiaroni J, Bailly P. A genetic strategy to control expression of human blood
group antigens in red blood cells generated in vitro. Transfusion. 2009; 49:967–976. [PubMed:
19175544]
Baum J, Pinder M, Conway DJ. Erythrocyte invasion phenotypes of Plasmodium falciparum in The
Gambia. Infect Immun. 2003; 71:1856–1863. [PubMed: 12654801]
Bei AK, Membi CD, Rayner JC, Mubi M, Ngasala B, Sultan AA, Premji Z, Duraisingh MT. Variant
merozoite protein expression is associated with erythrocyte invasion phenotypes in Plasmodium
falciparum isolates from Tanzania. Mol Biochem Parasitol. 2007; 153:66–71. [PubMed: 17303262]
Bei AK, Brugnara C, Duraisingh MT. In vitro genetic analysis of an erythrocyte determinant of
malaria infection. J Infect Dis. 2010; 202:1722–1727. [PubMed: 20958212]
Binks RH, Conway DJ. The major allelic dimorphisms in four Plasmodium falciparum merozoite
proteins are not associated with alternative pathways of erythrocyte invasion. Molecular and
biochemical parasitology. 1999; 103:123–127. [PubMed: 10514089]
Bushell KM, Sollner C, Schuster-Boeckler B, Bateman A, Wright GJ. Large-scale screening for novel
low-affinity extracellular protein interactions. Genome Res. 2008; 18:622–630. [PubMed:
18296487]
Chandramohanadas R, Davis PH, Beiting DP, Harbut MB, Darling C, Velmourougane G, Lee MY,
Greer PA, Roos DS, Greenbaum DC. Apicomplexan parasites co-opt host calpains to facilitate
their escape from infected cells. Science. 2009; 324:794–797. [PubMed: 19342550]
Chitnis CE. Molecular insights into receptors used by malaria parasites for erythrocyte invasion. Curr
Opin Hematol. 2001; 8:85–91. [PubMed: 11224682]
Cholera R, Brittain NJ, Gillrie MR, Lopera-Mesa TM, Diakite SA, Arie T, Krause MA, Guindo A,
Tubman A, Fujioka H, Diallo DA, Doumbo OK, Ho M, Wellems TE, Fairhurst RM. Impaired
cytoadherence of Plasmodium falciparum-infected erythrocytes containing sickle hemoglobin.
Proceedings of the National Academy of Sciences of the United States of America. 2008;
105:991–996. [PubMed: 18192399]
Cortes A, Benet A, Cooke BM, Barnwell JW, Reeder JC. Ability of Plasmodium falciparum to invade
Southeast Asian ovalocytes varies between parasite lines. Blood. 2004; 104:2961–2966. [PubMed:
15265796]
Crosnier C, Bustamante LY, Bartholdson SJ, Bei AK, Theron M, Uchikawa M, Mboup S, Ndir O,
Kwiatkowski DP, Duraisingh MT, Rayner JC, Wright GJ. Basigin is a receptor essential for
erythrocyte invasion by Plasmodium falciparum. Nature. 2011; 480:534–537. [PubMed:
22080952]
Cserti CM, Dzik WH. The ABO blood group system and Plasmodium falciparum malaria. Blood.
2007; 110:2250–2258. [PubMed: 17502454]
Bei and Duraisingh Page 8













Cyrklaff M, Sanchez CP, Kilian N, Bisseye C, Simpore J, Frischknecht F, Lanzer M. Hemoglobins S
and C Interfere with Actin Remodeling in Plasmodium falciparum-Infected Erythrocytes. Science.
2011; 334:1283–1286. [PubMed: 22075726]
Daily JP, Sabeti P. A malaria fingerprint in the human genome? N Engl J Med. 2008; 358:1855–1856.
[PubMed: 18420494]
Deans A-M, Nery S, Conway DJ, Kai O, Marsh K, Rowe JA. Invasion Pathways and Malaria Severity
in Kenyan Plasmodium falciparum Clinical Isolates. Infect Immun. 2007; 75:3014–3020.
[PubMed: 17438038]
Dolan SA, Miller LH, Wellems TE. Evidence for a switching mechanism in the invasion of
erythrocytes by Plasmodium falciparum. J Clin Invest. 1990; 86:618–624. [PubMed: 2200806]
Duraisingh MT, Triglia T, Ralph SA, Rayner JC, Barnwell JW, McFadden GI, Cowman AF.
Phenotypic variation of Plasmodium falciparum merozoite proteins directs receptor targeting for
invasion of human erythrocytes. EMBO J. 2003; 22:1047–1057. [PubMed: 12606570]
Facer CA. Merozoites of P. falciparum require glycophorin for invasion into red cells. Bull Soc Pathol
Exot Filiales. 1983; 76:463–469. [PubMed: 6370471]
Fairhurst RM, Baruch DI, Brittain NJ, Ostera GR, Wallach JS, Hoang HL, Hayton K, Guindo A,
Makobongo MO, Schwartz OM, Tounkara A, Doumbo OK, Diallo DA, Fujioka H, Ho M,
Wellems TE. Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect
against malaria. Nature. 2005; 435:1117–1121. [PubMed: 15973412]
Flint J, Harding RM, Boyce AJ, Clegg JB. The population genetics of the haemoglobinopathies.
Baillieres Clin Haematol. 1998; 11:1–51. [PubMed: 10872472]
Fraser GR, Giblett ER, Motulsky AG. Population genetic studies in the Congo. 3. Blood groups (ABO,
MNSs, Rh, Jsa). Am J Hum Genet. 1966; 18:546–552. [PubMed: 4959344]
Friedman MJ. Erythrocytic mechanism of sickle cell resistance to malaria. Proc Natl Acad Sci U S A.
1978; 75:1994–1997. [PubMed: 347452]
Galinski MR, Medina CC, Ingravallo P, Barnwell JW. A reticulocyte-binding protein complex of
Plasmodium vivax merozoites. Cell. 1992; 69:1213–1226. [PubMed: 1617731]
Giarratana M-C, Kobari L, Lapillonne H, Chalmers D, Kiger L, Cynober T, Marden MC, Wajcman H,
Douay L. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells.
Nat Biotechnol. 2005; 23:69–74. [PubMed: 15619619]
Giarratana MC, Rouard H, Dumont A, Kiger L, Safeukui I, Le Pennec PY, Francois S, Trugnan G,
Peyrard T, Marie T, Jolly S, Hebert N, Mazurier C, Mario N, Harmand L, Lapillonne H, Devaux
JY, Douay L. Proof of principle for transfusion of in vitro-generated red blood cells. Blood. 2011;
118:5071–5079. [PubMed: 21885599]
Gilles HM, Fletcher KA, Hendrickse RG, Lindner R, Reddy S, Allan N. Glucose-6-phosphate-
dehydrogenase deficiency, sickling, and malaria in African children in South Western Nigeria.
Lancet. 1967; 1:138–140. [PubMed: 4163314]
Gomez-Escobar N, Amambua-Ngwa A, Walther M, Okebe J, Ebonyi A, Conway DJ. Erythrocyte
invasion and merozoite ligand gene expression in severe and mild Plasmodium falciparum
malaria. J Infect Dis. 2010; 201:444–452. [PubMed: 20050806]
Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, Hadley TJ, Miller LH. A receptor for the
malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science. 1993;
261:1182–1184. [PubMed: 7689250]
Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, Eaves CJ, Cavilla B, Wadsworth LD,
Beuzard Y, Bouhassira EE, Russell R, London IM, Nagel RL, Leboulch P, Humphries RK.
Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral
integration in hematopoietic stem cells. Proc Natl Acad Sci USA. 2002; 99:14380–14385.
[PubMed: 12391330]
Jallow M, Teo YY, Small KS, Rockett KA, Deloukas P, Clark TG, Kivinen K, Bojang KA, Conway
DJ, Pinder M, Sirugo G, Sisay-Joof F, Usen S, Auburn S, Bumpstead SJ, Campino S, Coffey A,
Dunham A, Fry AE, Green A, Gwilliam R, Hunt SE, Inouye M, Jeffreys AE, Mendy A, Palotie A,
Potter S, Ragoussis J, Rogers J, Rowlands K, Somaskantharajah E, Whittaker P, Widden C,
Donnelly P, Howie B, Marchini J, Morris A, SanJoaquin M, Achidi EA, Agbenyega T, Allen A,
Amodu O, Corran P, Djimde A, Dolo A, Doumbo OK, Drakeley C, Dunstan S, Evans J, Farrar J,
Bei and Duraisingh Page 9













Fernando D, Hien TT, Horstmann RD, Ibrahim M, Karunaweera N, Kokwaro G, Koram KA,
Lemnge M, Makani J, Marsh K, Michon P, Modiano D, Molyneux ME, Mueller I, Parker M,
Peshu N, Plowe CV, Puijalon O, Reeder J, Reyburn H, Riley EM, Sakuntabhai A, Singhasivanon
P, Sirima S, Tall A, Taylor TE, Thera M, Troye-Blomberg M, Williams TN, Wilson M,
Kwiatkowski DP. Genome-wide and fine-resolution association analysis of malaria in West
Africa. Nat Genet. 2009; 41:657–665. [PubMed: 19465909]
Jennings CV, Ahouidi AD, Zilversmit M, Bei AK, Rayner J, Sarr O, Ndir O, Wirth DF, Mboup S,
Duraisingh MT. Molecular analysis of erythrocyte invasion in Plasmodium falciparum isolates
from Senegal. Infect Immun. 2007; 75:3531–3538. [PubMed: 17470537]
Jungery M. Studies on the biochemical basis of the interaction of the merozoites of Plasmodium
falciparum and the human red cell. Trans R Soc Trop Med Hyg. 1985; 79:591–597. [PubMed:
3913066]
Kaul DK, Roth EF Jr, Nagel RL, Howard RJ, Handunnetti SM. Rosetting of Plasmodium falciparum-
infected red blood cells with uninfected red blood cells enhances microvascular obstruction under
flow conditions. Blood. 1991; 78:812–819. [PubMed: 1859893]
Lantos PM, Ahouidi AD, Bei AK, Jennings CV, Sarr O, Ndir O, Wirth DF, Mboup S, Duraisingh MT.
Erythrocyte invasion profiles are associated with a common invasion ligand polymorphism in
Senegalese isolates of Plasmodium falciparum. Parasitology. 2009; 136:1–9. [PubMed: 19126266]
Le Scanf C, Vigan-Womas I, Contamin H, Guillotte M, Bischoff E, Mercereau-Puijalon O. Rosetting
is associated with increased Plasmodium falciparum in vivo multiplication rate in the Saimiri
sciureus monkey. Microbes Infect. 2008; 10:447–451. [PubMed: 18400545]
Lengerke C, Daley GQ. Autologous blood cell therapies from pluripotent stem cells. Blood Rev. 2010;
24:27–37. [PubMed: 19910091]
Lobo CA, Rodriguez M, Reid M, Lustigman S. Glycophorin C is the receptor for the Plasmodium
falciparum erythrocyte binding ligand PfEBP-2 (baebl). Blood. 2003; 101:4628–4631. [PubMed:
12576308]
Lobo C-A, de Frazao K, Rodriguez M, Reid M, Zalis M, Lustigman S. Invasion profiles of Brazilian
field isolates of Plasmodium falciparum: phenotypic and genotypic analyses. Infect Immun. 2004;
72:5886–5891. [PubMed: 15385490]
Mackinnon MJ, Mwangi TW, Snow RW, Marsh K, Williams TN. Heritability of malaria in Africa.
PLoS Med. 2005; 2:e340. [PubMed: 16259530]
Maier AG, Duraisingh MT, Reeder JC, Patel SS, Kazura JW, Zimmerman PA, Cowman AF.
Plasmodium falciparum erythrocyte invasion through glycophorin C and selection for Gerbich
negativity in human populations. Nat Med. 2003; 9:87–92. [PubMed: 12469115]
Miller LH, Haynes JD, McAuliffe FM, Shiroishi T, Durocher JR, McGinniss MH. Evidence for
differences in erythrocyte surface receptors for the malarial parasites, Plasmodium falciparum and
Plasmodium knowlesi. J Exp Med. 1977; 146:277–281. [PubMed: 327014]
Min-Oo G, Fortin A, Tam MF, Nantel A, Stevenson MM, Gros P. Pyruvate kinase deficiency in mice
protects against malaria. Nat Genet. 2003; 35:357–362. [PubMed: 14595440]
Mitchell GH, Hadley TJ, McGinniss MH, Klotz FW, Miller LH. Invasion of erythrocytes by
Plasmodium falciparum malaria parasites: evidence for receptor heterogeneity and two receptors.
Blood. 1986; 67:1519–1521. [PubMed: 3516259]
Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE. Transduction of human CD34+ cells that
mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science. 1999; 283:682–686.
[PubMed: 9924027]
Modiano D, Luoni G, Sirima BS, Simpore J, Verra F, Konate A, Rastrelli E, Olivieri A, Calissano C,
Paganotti GM, D'Urbano L, Sanou I, Sawadogo A, Modiano G, Coluzzi M. Haemoglobin C
protects against clinical Plasmodium falciparum malaria. Nature. 2001; 414:305–308. [PubMed:
11713529]
Murphy SC, Harrison T, Hamm HE, Lomasney JW, Mohandas N, Haldar K. Erythrocyte G protein as
a novel target for malarial chemotherapy. PLoS Med. 2006; 3:e528. [PubMed: 17194200]
Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M,
Lozano R, Lopez AD. Global malaria mortality between 1980 and 2010: a systematic analysis.
Lancet. 2012; 379:413–431. [PubMed: 22305225]
Bei and Duraisingh Page 10













Neildez-Nguyen TM, Wajcman H, Marden MC, Bensidhoum M, Moncollin V, Giarratana MC, Kobari
L, Thierry D, Douay L. Human erythroid cells produced ex vivo at large scale differentiate into
red blood cells in vivo. Nat Biotechnol. 2002; 20:467–472. [PubMed: 11981559]
Nery S, Deans AM, Mosobo M, Marsh K, Rowe JA, Conway DJ. Expression of Plasmodium
falciparum genes involved in erythrocyte invasion varies among isolates cultured directly from
patients. Mol Biochem Parasitol. 2006; 149:208–215. [PubMed: 16837080]
Ogun SA, Holder AA. A high molecular mass Plasmodium yoelii rhoptry protein binds to
erythrocytes. Mol Biochem Parasitol. 1996; 76:321–324. [PubMed: 8920020]
Okoyeh JN, Pillai CR, Chitnis CE. Plasmodium falciparum field isolates commonly use erythrocyte
invasion pathways that are independent of sialic acid residues of glycophorin A. Infect Immun.
1999; 67:5784–5791. [PubMed: 10531229]
Pasvol G, Weatherall DJ, Wilson RJ. Cellular mechanism for the protective effect of haemoglobin S
against P. falciparum malaria. Nature. 1978; 274:701–703. [PubMed: 353566]
Pasvol G, Jungery M, Weatherall DJ, Parsons SF, Anstee DJ, Tanner MJ. Glycophorin as a possible
receptor for Plasmodium falciparum. Lancet. 1982a; 2:947–950. [PubMed: 6127459]
Pasvol G, Wainscoat JS, Weatherall DJ. Erythrocytes deficiency in glycophorin resist invasion by the
malarial parasite Plasmodium falciparum. Nature. 1982b; 297:64–66. [PubMed: 7040988]
Pasvol G, Jungery M. Glycophorins and red cell invasion by Plasmodium falciparum. Ciba Found
Symp. 1983; 94:174–195. [PubMed: 6341001]
Pasvol G, Chasis JA, Mohandas N, Anstee DJ, Tanner MJ, Merry AH. Inhibition of malarial parasite
invasion by monoclonal antibodies against glycophorin A correlates with reduction in red cell
membrane deformability. Blood. 1989; 74:1836–1843. [PubMed: 2676019]
Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, Acharya SA, Ellis J,
London IM, Eaves CJ, Humphries RK, Beuzard Y, Nagel RL, Leboulch P. Correction of sickle
cell disease in transgenic mouse models by gene therapy. Science. 2001; 294:2368–2371.
[PubMed: 11743206]
Puthenveetil G, Scholes J, Carbonell D, Qureshi N, Xia P, Zeng L, Li S, Yu Y, Hiti AL, Yee JK, Malik
P. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector.
Blood. 2004; 104:3445–3453. [PubMed: 15292064]
Reed MB, Caruana SR, Batchelor AH, Thompson JK, Crabb BS, Cowman AF. Targeted disruption of
an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a
sialic acid-independent pathway of invasion. Proc Natl Acad Sci U S A. 2000; 97:7509–7514.
[PubMed: 10861015]
Roth EF Jr, Raventos-Suarez C, Rinaldi A, Nagel RL. Glucose-6-phosphate dehydrogenase deficiency
inhibits in vitro growth of Plasmodium falciparum. Proceedings of the National Academy of
Sciences of the United States of America. 1983; 80:298–299. [PubMed: 6337374]
Rowe JA, Moulds JM, Newbold CI, Miller LH. P. falciparum rosetting mediated by a parasite-variant
erythrocyte membrane protein and complement-receptor 1. Nature. 1997; 388:292–295. [PubMed:
9230440]
Rowe JA, Obiero J, Marsh K, Raza A. Short report: Positive correlation between rosetting and
parasitemia in Plasmodium falciparum clinical isolates. The American journal of tropical medicine
and hygiene. 2002; 66:458–460. [PubMed: 12201576]
Rowe JA, Handel IG, Thera MA, Deans A-M, Lyke KE, Koné A, Diallo DA, Raza A, Kai O, Marsh
K, Plowe CV, Doumbo OK, Moulds JM. Blood group O protects against severe Plasmodium
falciparum malaria through the mechanism of reduced rosetting. Proc Natl Acad Sci USA. 2007;
104:17471–17476. [PubMed: 17959777]
Rowe JA, Claessens A, Corrigan RA, Arman M. Adhesion of Plasmodium falciparum-infected
erythrocytes to human cells: molecular mechanisms and therapeutic implications. Expert Rev Mol
Med. 2009a; 11:e16. [PubMed: 19467172]
Rowe JA, Opi DH, Williams TN. Blood groups and malaria: fresh insights into pathogenesis and
identification of targets for intervention. Curr Opin Hematol. 2009b; 16:480–487. [PubMed:
19812491]
Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med. 1998;
76:581–588. [PubMed: 9694435]
Bei and Duraisingh Page 11













Sankaran VG, Xu J, Ragoczy T, Ippolito GC, Walkley CR, Maika SD, Fujiwara Y, Ito M, Groudine
M, Bender MA, Tucker PW, Orkin SH. Developmental and species-divergent globin switching are
driven by BCL11A. Nature. 2009; 460:1093–1097. [PubMed: 19657335]
Serjeantson SW. A selective advantage for the Gerbich-negative phenotype in malarious areas of
Papua New Guinea. P N G Med J. 1989; 32:5–9. [PubMed: 2750321]
Sicard A, Semblat JP, Doerig C, Hamelin R, Moniatte M, Dorin-Semblat D, Spicer JA, Srivastava A,
Retzlaff S, Heussler V, Waters AP. Activation of a PAK-MEK signalling pathway in malaria
parasite-infected erythrocytes. Cellular microbiology. 2011; 13:836–845. [PubMed: 21371233]
Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH. Receptor and ligand domains for invasion
of erythrocytes by Plasmodium falciparum. Science. 1994; 264:1941–1944. [PubMed: 8009226]
Spadafora C, Awandare GA, Kopydlowski KM, Czege J, Moch JK, Finberg RW, Tsokos GC, Stoute
JA. Complement receptor 1 is a sialic acid-independent erythrocyte receptor of Plasmodium
falciparum. PLoS Pathog. 2010; 6 e1000968.
Teo YY, Small KS, Kwiatkowski DP. Methodological challenges of genome-wide association analysis
in Africa. Nat Rev Genet. 2010; 11:149–160. [PubMed: 20084087]
Tham WH, Wilson DW, Lopaticki S, Schmidt CQ, Tetteh-Quarcoo PB, Barlow PN, Richard D,
Corbin JE, Beeson JG, Cowman AF. Complement receptor 1 is the host erythrocyte receptor for
Plasmodium falciparum PfRh4 invasion ligand. Proc Natl Acad Sci U S A. 2010; 107:17327–
17332. [PubMed: 20855594]
Thompson JK, Triglia T, Reed MB, Cowman AF. A novel ligand from Plasmodium falciparum that
binds to a sialic acid-containing receptor on the surface of human erythrocytes. Mol Microbiol.
2001; 41:47–58. [PubMed: 11454199]
Uneke CJ. Plasmodium falciparum malaria and ABO blood group: is there any relationship? Parasitol
Res. 2007; 100:759–765. [PubMed: 17047997]
WHO. Geneva, Switzerland: World Health Organizaion; 2010. World Malaria Report 2010.
Williams TN. Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006; 9:388–
394. [PubMed: 16815736]
Bei and Duraisingh Page 12














► Approaches for the functional analysis of erythrocyte determinants of malaria
infection are described.
► Methods to identify critical host surface molecules required for erythrocyte
invasion by Plasmodium parasites are emphasised.
► Potential for transgenic manipulation of erythrocytes in vitro is described.
► Pros and cons of the different technologies used for molecular analysis of the
erythrocyte are identified.
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Host-parasite interactions that facilitate erythrocyte invasion and erythrocyte remodeling.
(A) The erythrocytic stage of the Plasmodium life cycle depends on host proteins at a
number of stages: schizont maturation, merozoite egress, merozoite attachment, merozoite
invasion, and intracellular growth and parasite protein trafficking to the surface of the
infected erythrocyte. Throughout this process, host Calpain-1 has been determined to be
critical for parasite escape from the parasitophorous vacuole and erythrocyte egress, binding
to erythrocyte blood group receptors has been shown to be required for invasion, signaling
via G-protein coupled receptors (GPCRs) and host kinases have been shown to be necessary
for intracellular establishment, and normal hemoglobin has been shown to be required for
proper actin network formation and parasite adhesive protein export to the surface of the
erythrocyte. (B) The host-parasite interface is shown in detail with respect to the invading
merozoite. Parasite invasion ligands (Parasite Determinants) and human erythrocyte
receptors (Host Determinants) which have been identified to date are shown. Host receptor
modifications (glycosylation and terminal sialic acid residues) are shown. GPA, glycophorin
A; GPB, glycophorin B; GPC, glycophorin C; CR1, complement receptor 1; BSG, Basigin;
EBA, erythrocyte binding antigen; Rh, reticulocyte binding protein homolog.
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Methodologies employed for functional analysis of erythrocyte determinants of Plasmodium
invasion and growth. Various experimental procedures have been employed to target both
cytoplasmic and surface exposed erythrocyte determinants of invasion. Experiments
employing naturally occurring mutants, biochemical approaches, chemical biological
approaches and transgenic approaches have been used to identify and confirm the role of
host determinants of invasion via absence, interference, ectopic expression, and over-
expression. shRNA KD, small hairpin RNA knock-down.
Bei and Duraisingh Page 15

























Bei and Duraisingh Page 16
Table 1
Summary of approaches for analysis of erythrocyte determinants of 698 Plasmodium infection.
Approach Pros Cons
Natural Mutants
Assays using natural erythrocyte
mutants
Polymorphisms selected by nature
(physiologically relevant)
Viable erythrocytes naturally obtained
Confounding polymorphisms also present
Difficult to control experiments with cells from
different donors
Inability to complement the mutation
Functional genomics of natural
mutants
Using natural selection to identify novel
candidate resistance/susceptibility loci
Weak signals due to (weak) linkage disequilibrium
To date, GWAS has required further deep
sequencing to uncover signals
Biochemical Approaches
Pull-down Detects physiologically interacting proteins, ex
vivo or in vitro, with or without cross-linkers
Possible that weak interactions will not be detected
by pull-down
Gel-overlay, Erythrocyte binding
assays (EBAs) with enzyme treated
erythrocytes
Can use both antibody mediated detection or
radioactive methods
Protein abundance and stability can effect the
sensitivity
Requires stable protein interactions
Invasion assays with enzyme treated
erythrocytes
Determine the effect of removing sets of
receptors in the same genetic background on
parasite invasion
Non-specific removal of receptors. Removes
groups of both known and unknown receptors.
Antibody mediated inhibition Specific inhibition of a receptor by blocking
access to the parasite ligands
Can determine the effect of blocking a given
receptor in the same genetic background
High throughput
Antibody dependent (not all antibodies are
inhibitory)
Agglutination
Off target effects of antibodies (can impact both
invasion and membrane rigidity, for example)
Avexis Pentamerizing the bait or prey increases
detection of transient interactions
Limited by what can be expressed (size,
glycosylation, number of transmembrane domains)
False positives
Chemical genetic Approaches
Chemical inhibition Potent inhibition can be achieved
Temporal inhibition can be achieved
Depending on the inhibitor, inhibition can be
reversed
Off-target effects
Specificity of inhibition can be dependent on
concentration
Host versus parasite specificity can be a narrow
window, and difficult to achieve
Immunodepletion of cytoplasmic
proteins
The alternative to transgenic modification with
the same result – specific depletion of a given
protein
Limited to cytoplasmic proteins
Transgenic Approaches
shRNA Knock-down Stable and either inducible or constant
Amenable to forward genetic screens
Can study the effect of the absence (or
decrease) of a given protein in the erythrocyte
Level of knock-down varies depending on the gene
Knock-down (rather than knock-out) can be
insufficient to yield a phenotype
Erythrocyte viability can be effected depending on
when the knock-down has an effect
May be necessary to induce knock-down later in
erythropoiesis to avoid developmental effects
Ectopic expression Inducible expression, varying level of
expression, can be achieved with specific
vectors and promoters
Matching physiologic levels of expression with
appropriate promoters
Allelic replacement Complementation is possible (ectopically
expressing a protein in a null background)
Must codon optimize the transgenically expressed
allele to avoid shRNA mediated KD of
replacement as well as endogenous
Matching levels of expression with appropriate
promoters
GWAS, genome-wide association study; shRNA, small hairpin RNA; KD, knock down; AVEXIS, avidity-based extracellular interaction screen.
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